Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Centrine Tablets

This page contains information on Centrine Tablets for veterinary use.
The information provided typically includes the following:
  • Centrine Tablets Indications
  • Warnings and cautions for Centrine Tablets
  • Direction and dosage information for Centrine Tablets

Centrine Tablets

This treatment applies to the following species:
Manufacturer: Zoetis


Veterinary Injection and Tablets

NADA 43-079, Approved by FDA

NADA 43-078, Approved by FDA


CENTRINE (aminopentamide hydrogen sulfate) is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine.


CENTRINE effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine.

CENTRINE effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility.

The mydriatic and salivary effects of CENTRINE are less than those produced by atropine at similar dosage, permitting the control of vomiting and diarrhea with less distress to the animal due to dryness of the mouth and blurred vision.

Centrine Tablets Indications

CENTRINE is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea.


CENTRINE should not be used in animals with glaucoma because of the occurrence of mydriasis.




Dryness of the mouth is the most commonly reported side effect. Blurring of vision may occur and dryness of the eyes may occur if larger (greater than therapeutic) doses are used. CENTRINE should be used cautiously, if at all, in pyloric obstruction because of its action in delaying gastric emptying. These effects frequently decrease with continued administration of the drug. Disturbances in urination are relatively infrequent. They vary from slightly hesitancy in initiating urination to complete inability to urinate; the latter is an indication for discontinuing the drug. After a day or two, it may be resumed at a lower dosage level.


CENTRINE (aminopentamide hydrogen sulfate) may be administered by subcutaneous or intramuscular injection or by oral tablets according to the following schedule. If the desired effect is not obtained, the dosage may be gradually increased up to a maximum of 5 times the doses listed. When the condition has been brought under control by parenteral medication, treatment can be continued, if desired, with 0.2 mg scored tablets according to the dosage schedule.

Weight of Animal

Amount to be Administered Every 8 to 12 hours


Injectable Volume

Oral Tablets

10 lbs or less

0.1 mg

0.2 mL

1/2 Tab

11 lbs to 20 lbs

0.2 mg

0.4 mL

1 Tab

21 lbs to 50 lbs

0.3 mg

0.6 mL

1 1/2 Tabs

51 lbs to 100 lbs

0.4 mg

0.8 mL

2 Tabs

Over 100 lbs

0.5 mg

1.0 mL

2 1/2 Tabs

Centrine Tablets Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

How Supplied

0.5 mg/mL CENTRINE (aminopentamide hydrogen sulfate) VETERINARY INJECTION, 10 mL vials.

0.2 mg CENTRINE (aminopentamide hydrogen sulfate) VETERINARY TABLETS, bottles of 100.

NDC 0856-2401-10 - 0.5 mg/mL - 10 mL vials.

NDC 0856-2400-60 - 0.2 mg - bottles of 100.

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Fort Dodge Animal Health, Fort Dodge, Iowa 50501 USA


Rev. September 1996


NAC No.: 10030331

Telephone:   269-833-4000
Customer Service:   800-733-5500 and 800-793-0596
Veterinary Medical Investigations & Product Support:   800-366-5288
Technical Services (USA):   800-366-5288
Every effort has been made to ensure the accuracy of the Centrine Tablets information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2018 North American Compendiums. Updated: 2018-02-26